Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Chemotherapy, Personalized

Key genes can predict sensitivity to toxin

Genetic tests can indicate whether a given person is at risk for certain diseases. But recent work by MIT scientists suggests that it may soon be possible to test how well people will tolerate toxic compounds, as well. Such tests could even enable doctors to predict how a given patient will respond to specific chemo­therapy drugs.

The scientists, led by Leona Samson, director of MIT’s Center for Environmental Health Sciences and professor of biological engineering and biology, first measured gene expression in cells from 24 healthy people in a genetically and ethnically diverse population sample. Then they exposed these cell lines to a DNA-damaging agent, MNNG. By comparing gene expression in the four most sensitive and the four most resistant cell lines, they were able to zero in on 48 key genes correlated with MNNG sensitivity. By measuring the activity of these standouts alone, without examining every gene, they found that they could predict, with 94 percent accuracy, whether any of the remaining cell lines would stand up to the toxic compound. Because the cell lines came from a diverse group of subjects, the test should be widely applicable in the general population.

This story is part of the March/April 2009 Issue of the MIT News magazine
See the rest of the issue
Subscribe

Samson says that the group already knew of a dozen genes linked to MNNG resistance, but this study scanned for all potential candidates, identifying 450 that were differently expressed. “We found an incredible number,” she says. “That made us realize that there are a whole lot of other things going on that are important for protecting against damaging agents.”

MNNG was an ideal test subject because it’s similar to toxic compounds found in common chemotherapy drugs and tobacco smoke. Now Samson’s group is expanding the study to chemotherapeutic agents. She hopes that in the long run, the group’s work will lead to tests that can determine which drugs will be most effective in killing a particular tumor and, just as important, how well a patient’s healthy cells will resist that compound’s toxic action. “You want to kill the tumor but you don’t want to kill the person,” Samson says. And while she’s hesitant to speculate, she’s hopeful about the potential of the work: “The important thing is finding the most effective treatment for each individual patient. It’s really thinking toward the possibility of personalized medicine.”

Cut off? Read unlimited articles today.

Become an Insider
Already an Insider? Log in.
Next in MIT News
Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    Print Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.